Bristol-Myers Squibb

Latest news

• What Does Bristol Myers Squibb (BMY) Gain From Its Broader Heart Drug Approval? (opens in a new tab)

  Simply Wall Street · Oct 2, 2026

• AbbVie vs. Bristol Myers Squibb: A Clash Between Growth Premium and Value Trap (opens in a new tab)

  NAI500 · Oct 2, 2026

• AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? (opens in a new tab)

  fool.com · Oct 1, 2026

• Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day (opens in a new tab)

  MarketWatch · Oct 1, 2026

• Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale (opens in a new tab)

  fool.com · Oct 1, 2026

• Bristol Myers Squibb (BMY) Boosts Champions in Care Initiative w (opens in a new tab)

  GuruFocus · Oct 1, 2026

• Bristol Myers Squibb Deepens Commitment To Healthcare Professionals Through Champions In Care Movement (opens in a new tab)

  TradingView · Oct 1, 2026

• Bristol Myers Squibb secures expanded US approval for Camzyos (opens in a new tab)

  Yahoo · Oct 1, 2026

• What You Could Reuse From Bristol Myers Squibb's 46% Gain (opens in a new tab)

  Simply Wall Street · Sep 30, 2026

• Bristol Myers trial revisions shake confidence in new class of fibrosis drugs (opens in a new tab)

  BioPharma Dive · Sep 30, 2026

• Bristol Myers Squibb’s Dividend Sustainability Hinges on One Critical Cash Flow Metric (opens in a new tab)

  Yahoo Finance · Sep 30, 2026

• Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know (opens in a new tab)

  Yahoo Finance · Sep 30, 2026

• How Strong Phase 3 MRD Data for ZENBEXUS in Myeloma Could Impact Bristol Myers Squibb (BMY) Investors (opens in a new tab)

  Yahoo Finance · Sep 30, 2026

• Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? (opens in a new tab)

  fool.com · Sep 29, 2026

• Potential liver safety issue seen in phase 3 trial for Bristol's admilparant (opens in a new tab)

  Seeking Alpha · Sep 29, 2026

• Bristol Myers Squibb (BMY) Reported 41.1% MRD Negative Responses In Phase 3 Trial (opens in a new tab)

  Yahoo Finance · Sep 29, 2026

• Why Is Bristol-Myers Squibb (BMY) In Focus After New Phase 3 Myeloma Data? (opens in a new tab)

  Simply Wall Street · Sep 29, 2026

• 3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation (opens in a new tab)

  fool.com · Sep 29, 2026

• Bristol Myers Squibb (BMY) Stock Trades Below Fair Value As Caution Lingers (opens in a new tab)

  Yahoo Finance · Sep 29, 2026

• Could Bristol-Myers Squibb (BMY)’s New Myeloma Data Reshape its Growth Outlook? (opens in a new tab)

  Yahoo Finance · Sep 29, 2026

• Bristol-Myers Squibb (BMY) is Building its Next Growth Engine. Can It Replace Lost Revenue? (opens in a new tab)

  Yahoo Finance · Sep 28, 2026

• Bristol Myers Squibb Co. stock outperforms competitors on strong trading day (opens in a new tab)

  MarketWatch · Sep 28, 2026

• Care Within Reach: How the Bristol Myers Squibb Foundation Is Strengthening Health Systems Across Africa (opens in a new tab)

  Yahoo Finance · Sep 28, 2026

• Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? (opens in a new tab)

  Yahoo Finance · Sep 27, 2026

• Exploring New CAR-T Approaches for Relapsed Multiple Myeloma – Bristol Myers Squibb (opens in a new tab)

  Oncodaily · Sep 25, 2026

• Rx Rundown: Lilly, Bristol Myers Squibb, Johnson & Johnson and more (opens in a new tab)

  Medical Marketing and Media · Sep 25, 2026

• What Bristol Myers Squibb Stock’s Strong Buy Upgrade Means For Shareholders (opens in a new tab)

  Simply Wall Street · Sep 25, 2026

• Bristol Myers Squibb’s Zenbexus shows improved response rates (opens in a new tab)

  Investing.com · Sep 25, 2026

• Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma (opens in a new tab)

  Business Wire · Sep 25, 2026

• Bristol Myers Squibb (NYSE:BMY) Upgraded to Strong-Buy at Zacks Research (opens in a new tab)

  MarketBeat · Sep 25, 2026